AB S T R A C T An abnormal triglyceride-rich lipoprotein has been isolated from some patients with chronic renal failure or severe hypertriglyceridemia. The abnormal lipoprotein was characterized by an increased content of apolipoprotein (apo) C-III-2 (57.5% of total apo C-III peptides compared with 35.5% for controls, P < 0.001) as characterized by isoelectric focusing and scanning densitometry. As determined by a substrate competition assay, the abnormal lipoprotein was a less efficient substrate for purified bovine milk lipoprotein lipase than control lipoproteins. Neuraminidase digestion of abnormal or control lipoprotein resulted in a reduction of the apo C-III-2 band with a corresponding increase in the region of apo C-III-0, which suggests that the increased content of apo C-III-2 in the abnormal is due to excessive sialylation of the C-III peptide. Limited incubation of the abnormal lipoproteins with neuraminidase caused a partial loss of sialic acid and resulted in a triglyceride-rich lipoprotein with a normal C-III-2:C-III-1 ratio. This preparation displayed normal substrate interaction with lipoprotein lipase. Three severely hypertriglyceridemic patients with the abnormal lipoprotein showed a marked reduction in serum triglyceride concentration, which is associated with a reversion to a normal C-peptide profile after dietary therapy. The results suggest that the extent of sialylation of the apo C-III peptide carried on triglyceride-rich lipoproteins may be critical for their interaction with lipoprotein lipase.
INTRODUCTION
The triglyceride-rich lipoproteins are cleared from the circulation by the action of lipoprotein lipase (E.C.
3.1.1.34) (1) . This enzyme is secreted from parenchymal cells such as adipoctyes and acts at the capillary endothelium to hydrolyze the triglyceride moiety of chylomicrons and very low density lipoproteins (VLDL)' with some accompanying hydrolysis of phospholipid (2) . In conditions where lipoprotein lipase is absent or greatly reduced in peripheral tissues (type 1 hyperlipidemia and insulin-deficient states), there is an associated gross hypertriglyceridemia (3, 4) .
The enzyme requires the presence of an activator peptide, apolipoprotein (apo) C-II, carried on VLDL and chylomicrons for maximal triglyceride hydrolysis to occur. The importance of this peptide in vivo is shown by the impaired degradation of triglyceriderich lipoproteins in patients with familial or acquired apo C-II deficiency, which results in a severe hypertriglyceridemia (5, 6) . This hypertriglyceridemia exists despite adequate levels of lipoprotein lipase activity in postheparin plasma or adipose tissue. Infusions of plasma as a source of apo C-II produces a rapid clearance of the hypertriglyceridaemia in both inherited and acquired types of disease.
There have been reports that other surface peptides on triglyceride-rich lipoproteins may modify the activity of lipoprotein lipase. For example apo C-III has been shown to inhibit the activity of the enzyme in vitro (7) . However, this peptide displays at least three isomorphic forms, which differ according to their sialic acid content. Thus apo C-III-0, C-Ill-1, and C-III-2 contain 0, 1, and 2 molecules of sialic acid, respectively, per molecule of peptide (8) .
Alterations in the relative proportions of the apo C-III isoforms have been previously observed under various dietary and metabolic states. Thus, in streptozotocin-induced diabetic rats fed a high sucrose diet, there was an increased content of apo C-III-2 and re-duced content of apo C-III-0 in their triglyceride-rich lipoproteins (9) . In rats fed a high carbohydrate diet, the relative proportions of apo C-III-0 increased, whereas apo C-III-3 fell in plasma VLDL (10) . And in humans fed a high-carbohydrate fat-free diet for 7 d there was an increase of apo C-III-0 relative to the other C-peptides on VLDL (11) .
We have previously reported in preliminary form a variant triglyceride-rich lipoprotein from two hypertriglyceridemic subjects that contained an excess proportion of apo C-III-2, as characterized by polyacrylamide gel electrophoresis (12 Further blood samples were obtained from patients with chronic renal failure (three dialyzed and one nondialyzed) attending the Renal Unit of St. Bartholomew's Hospital, and from subjects attending the Diabetic and Lipid Clinics. Analysis of the C-peptide content of triglyceride-rich lipoproteins by polyacrylamide gel electrophoresis identified those patients whose triglyceride-rich lipoproteins contained a relative excess of apo C-III-2 peptide as previously described (12) . Table I An alternative method for the initial isolation of triglyceride-rich lipoproteins used the density gradient centrifugation method (13) . The serum was adjusted to a density of 1.22 by the addition of 0.32 g of NaBr/ml of serum. This mixture was then layered below a continuous NaCl/NaBr gradient of density range 1.006-1.2, and centrifuged for 2 h at 28,000 rpm in an MSE 3 X 25-ml swing-out rotor. The lipoprotein layer at the surface of the gradient was collected with a pipette and purified by recentrifugation in isotonic NaCl/EDTA (0.195 mmol/liter and 0.27 ;tmol/liter) as described above. In some experiments, chylomicrons were prepared by ultracentrifugation of serum for 1 h at 25,000 rpm in an angle-head rotor, followed by recentrifugation in NaCl/EDTA as described above.
Analysis of apoproteins
Polyacrylamide gel electrophoresis. The method used for the analysis of the C peptides has been described in full detail by Kane (14) .
Isoelectric focusing. The lipoproteins were delipidated with ethanol:ether as described by Scanu and Edelstein (15) . The apoproteins were dissolved in freshly prepared urea 6 mol/liter and then subjected to flat-bed isoelectric focusing at pH 4-6. Details of the procedure have been given previously (16) . In brief, 100-200 ,ug of protein was applied to polyacrylamide gels with the following composition: 6 Partial desialylation of the lipoprotein was achieved by incubation with the enzyme as above for only 5 min. Enzyme activity was stopped by the addition of solid bromide (to a concentration of 3.1 mmol/liter), followed by storage in an ice bath at 4°C. The incubation mixtures were then introduced under the density gradient described above, and centrifuged for 2 h in the swing-out rotor. After this and subsequent washing and centrifuging steps, the neuraminidasetreated and control lipoproteins were concentrated by ultrafiltration with an Amicon PM1O membrane ( (Fig. 1) . This indicates that lipoprotein particle size is probably not an important factor in the substrate competition assay with triglyceride emulsion.
RESULTS
Apoprotein composition. Scans of representative isoelectric focusing gels of abnormal and control triglyceride-rich lipoproteins are shown in Fig. 2 (Fig. 4) . When )ensitometric scans all the apo C-III-2 was removed, however, the particle C-III-2 and C-III-1 showed strong and opposite correlations with the degree of hydrolysis by lipoprotein lipase but no correlation was observed with apo C-III-0. Reversibility of the C-III-2 excess in vivo. The abnormal lipoproteins of three severely hypertriglyceridemic diabetic patients were restudied after their serum triglyceride concentrations had been reduced by dietary therapy. The C-peptide composition of the variant lipoprotein reverted towards the normal pattern and their reaction with lipoprotein lipase also improved, which shows that this is a reversible phenomenon, (Table III) .
DISCUSSION
The composition of the C-peptides of human triglyceride-rich lipoproteins, first described in detail by Shore and Shore (20) and by Kane (14) , appears to be similar to the proportions found in most hypertriglyceridemic subjects (21) . In this paper, however, we describe an abnormal triglyceride-rich lipoprotein from two sources of patients (chronic renal failure and severe hypertriglyceridemia) that appears to contain excess apo C-III-2. This was identified by two different 1.6 2.0 electrophoretic systems (acrylamide gel and isoelectric focusing) and the isoelectric point of the densely staintriglyceride-ing band of the variant is similar to that of control apo .ipoprotein ii-C-III-2. The disappearance of this band in gels obitein to act as tained from the abnormal and control lipoproteins aflbedipnsMseth-ter digestion with neuraminidase, with the concomi-5) (i) and of tant increase in staining in the region of apo C-III-0, (0). also suggests a common identity of apo C-III-2 be- The latter experiments also suggest that excess sialylation of the C-III peptide is responsible for the abnormality. The physiological mechanisms governing the extent of sialylation of apo C-III are poorly understood. The changes we observed could be due to increased sialylation reactions during synthesis of the Cpeptides or impaired desialylation during their catabolism. Different mechanisms could be operating to produce increased sialylation of apo C-III in different patient groups. Sialylation of apo C-III peptides occur in the Golgi body of rat liver and the extent of sialylation increases with the residence time of the nascent VLDL particle in this organelle (22) . If there is delay in the transit of VLDL through the Golgi body in our patients with severe hypertriglyceridemia, this may account for the increased sialylation of their C-III peptides. Very little is known concerning the catabolism of human apo C-III, but this may occur partly in the kidney and may be altered in severe renal disease.
There are other examples where excess sialylation of a protein occurs and alters its functional properties. For example, in patients with severe liver disease there is excess sialylation of fibrinogen on the y-chains, and this renders it a less efficient substrate for thrombin, consequently prolonging the thrombin time (23) .
The increased apo C-III-2 content of the abnormal lipoprotein is unlikely to be due to the hypertriglyceridemia per se as our control hypertriglyceridemic group did not show a similar abnormality. Whatever the cause of the increased apo C-III-2 content of the variant lipoproteins, it was associated with impaired substrate interaction with lipoprotein lipase in vitro. Where reversion to a normal apoprotein composition occurred after dietary therapy, there was an improvement in the lipoprotein-enzyme interaction, which suggest that the impaired substrate efficiency of the particle with lipoprotein lipase may be a contributing factor to the etiology of the hypertriglyceridemia. Excess sialylation is unlikely to be a major factor, however, since the abnormal pattern was observed in two patient groups with widely differing mean plasma triglycerides (82 and 2.6 mmol/liter, respectively). Thus, hypertriglyceridemia can occur without the C-III abnormality and the C-III abnormality can occur without severe hypertriglyceridemia. The development of hypertriglyceridemia may be the resultant of many factors, of which excess sialylation of apo C-III may be just one. On its own it may impair triglyceride clearance in vivo but not enough to produce hypertriglyceridemia. However, in association with increased hepatic production of triglyceride-rich lipoproteins, hypertriglyceridemia may develop. When the variant lipoprotein was treated with neuraminidase to produce a normal C-III-2:C-III-1 ratio, the substrate behavior of the modified lipoprotein was normal. However, when the apo C-III-2 content is further reduced by prolonged incubation with neuraminidase, the particle becomes a less efficient substrate for the enzyme, which suggests that some apo C-III-2 is required for optimal enzyme-substrate interaction.
We have previously reported variant lipoproteins associated with hypertriglyceridemia displaying im- suggests that the covalent linkage of the second sialic acid residue to the apo C-III peptide may be critical for optimal hydrolysis of triglyceride-rich lipoprotein by the enzyme.
